Market Research Reports and Industry Reports

MITSUBISHI TANABE , Outperform - Invokana: Nice to Have A Clean Label, Yet A Long Way To Go Before Gaining Full Confidence!

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Invokana clean label thrills many on the street rising hopes that Invokana sales could cross $2.5b+ at peak. However we think that CV issues (dose dependent increase in LDL, CV events observed in first 30 days in CANVAS study), associated genital/UTI infections, compromised efficacy in renally impaired patients and long term safety study requirements by FDA (Table 1), should be seen in conjunction with the clean label. These issues will limit the initial uptake of Invokana to a small segment of diabetic patients - we think patients moving to triple OAD, on GLP-1 or Insulin (due to insufficient control from existing therapies, and escalating disease) are the broader target base of Invokana. Within this broader patient pool, ~40% patients with renal risks, >30% obese patients with co-morbid conditions and CV risks, and females at high UTI infection risk need to be restricted further this leaves a merely ~263k (or ~2.1% of total OAD patients) patients in the US for SGLT-2 inhibitors
Taking All Factors into Account, We arrive the Following Target Patient Base for Invokana (Table 4, 5- Invokana Market Model):.
We expect the market share to split between Invokana: Empagliflozin: Dapagliflozin by ~55:35:10 respectively as
Based on the available data comparision of Empagliflozin vs. Invokana, its efficacy looks better than Empagliflozin. While on safety front, based on PhIIb data empagliflozin reported less genital mycotic infections and equivalent UTI infection to Invokana when indirectly compared.
N/A

List Of Tables

N/A

List Of Figures

N/A

Mitsubishi Gas Chemical Co Inc (4182) - Financial and Strategic SWOT Analysis Review

Mitsubishi Gas Chemical Co Inc (MGC) is a chemical company that manufactures and markets basic chemicals, specialty chemicals and advanced materials. The company offers products such as natural gas chemicals,

USD 300View Report

Elicio/Eneco/Mitsubishi – Norther Offshore Wind Farm 370 MW – Flamande Project Profile

Synopsis Elicio/Eneco/Mitsubishi Norther Offshore Wind Farm 370 MW Flamande Project Profile contains information on the scope of the project including project overview and location. The profile also details project

USD 75View Report

Mitsubishi Pencil Co Ltd in Personal Accessories (Japan)

Mitsubishi Pencil uses the slogan The finest quality is the best service in its corporate communications and continues to offer high-quality and high added-value products. The companys core business is

USD 150View Report

Mitsubishi Tanabe Partnering Deals and Alliances 2010 to 2017

The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the worlds leading life sciences companies.On demand company reports are prepared

USD 1495View Report

Mitsubishi Tanabe Pharma Corp (4508) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Mitsubishi Tanabe Pharma Corp (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, is a pharmaceutical company. The company identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC)

USD 250View Report

Mitsubishi Tanabe Pharma Corporation - Strategy, SWOT and Corporate Finance Report

Mitsubishi Tanabe Pharma Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the companys structure, operation, SWOT analysis, product

USD 175View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 500
  • Site Licence    $ 1000
  • Enterprisewide Licence    $ 1500
$ 500

Reports Details

Published Date : Apr 2013
No. of Pages :9
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube